ARCHIVES

Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific

This article is from The Cancer Letter archive.

Vol. 37 No. 32 | August 12, 2011

Download PDF Visit The Full Archive

Related Articles

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

October 26, 2012

NCAB Approves 8 Cancer Centers As Comprehensive

October 4, 1991

In Brief: Pittsburgh Joins List Of Comprehensive Center Prospect; FDA Schedules Meeting On Cancer Drugs

July 11, 1975

The FY 1984 Bypass Budget: How NCI Would Spend the Money

July 9, 1982

Cancer Letter Adds Associate Editor

July 19, 1985

NCA Asks HHS To Exempt From DRG Peer Reviewed Institutions With At Least 25 Protocol Patients

August 12, 1983